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Introduction {#sec1}
============

It is increasingly recognized that tumors do not simply depend on their own proliferative capacity for growth, but instead interact with their environment on multiple levels. For example, the tumor microenvironment can have a growth-enhancing role by inducing a wound healing like pro-proliferative milieu \[[@bib1]\] or by recruiting tumor enhancing cancer-associated fibroblasts \[[@bib2], [@bib3]\]. However, in certain instances, tumor-host interactions have also been reported to inhibit tumor growth \[[@bib4]\]. For example, embryonic environments have been shown to suppress the aggressiveness of multiple cancer cells \[[@bib5], [@bib6]\]. In addition, in some contexts, fibroblasts have been shown to limit the growth and malignancy of neoplastic cells \[[@bib7]\]. This suggests that understanding how to enhance the tumor suppressive properties of host tissues may help in the fight against cancer.

Reciprocally, it has also been suggested that precancerous lesions and growing tumors could adversely affect the host tissue. Specifically, it has been proposed that tumor cells could kill surrounding normal cells and use this strategy to clear space in which they can expand. This suggestion stems from the observation that in developing tissues, cells with tumor promoting mutations can induce cell death in nearby wild-type cells \[[@bib8], [@bib9]\]. In particular, it has been suggested that cancer cells co-opt a form of cell interaction normally present in tissues, known as cell competition \[[@bib10], [@bib11]\]. Cell competition was originally discovered in *Drosophila* when it was found that wild-type cells can kill cells with mutations that reduce their fitness and growth potential \[[@bib12]\] and has been suggested to act as a quality-control mechanism to preserve tissue function \[[@bib13], [@bib14]\]. It was later found that in developing tissues, wild-type cells themselves could be killed via cell competition by mutant cells harboring oncogenic mutations, so called supercompetitor cells \[[@bib8], [@bib9]\]. This led to the long-standing hypothesis that tumor-host cell competition might take place and promote tumor formation; however, this has never been tested directly in adult tissues.

The adult *Drosophila* midgut has recently been established as a model system to study adult stem cell behavior, tissue homeostasis, aging, and regeneration \[[@bib15], [@bib16], [@bib17]\]. This tissue has a high cellular turnover and is maintained by newly differentiated cells produced from intestinal stem cells (ISCs), in a way that is remarkably similar to the mammalian intestine \[[@bib17]\]. Importantly, mutations that are involved in cancer have also been found to lead to overgrowth and tumor formation in the fly intestine \[[@bib18], [@bib19], [@bib20]\], in some cases by niche appropriation \[[@bib21]\]. Furthermore, we have recently shown that cell competition is active and plays a role in shaping tissue colonization in this tissue \[[@bib22]\]. Overall, these features provide a unique opportunity to combine the power of *Drosophila* genetics and the simplicity of this adult homeostatic tissue to study the role of cell competition in tumor formation.

Here we show that *Drosophila* intestinal tumors compete with and induce elimination of surrounding cells, causing host tissue attrition. Importantly, we demonstrate that preventing cell competition, e.g., by inhibiting cell death, dramatically reduces tumor growth. Thus, by generating an environment permissive for tumor growth, tumor-induced cell competition acts as a key driver of tumorigenesis in this tissue, providing a novel angle to counter tumor expansion.

Results {#sec2}
=======

*APC*^*−/−*^ Adenomas Induce Apoptosis in Surrounding Cells {#sec2.1}
-----------------------------------------------------------

To investigate whether cell competition takes place at sites of pre-cancerous lesions, we used mutations in the *Adenomatous polyposis coli* (*Apc*) genes, which cause hyper activation of the Wnt pathway and induce hyperplasia and benign tumor formations (hereafter referred to as adenomas) in the adult *Drosophila* midgut \[[@bib19], [@bib20]\]. We focused on Wnt-induced adenomas because we previously showed that in developing tissues, cells with increased Wnt signaling can adopt a supercompetitor phenotype and cause elimination of normal cells \[[@bib23]\]. In addition, the mechanisms driving *APC*^−/−^ hyperplasia in the fly show important similarities with *APC*^−/−^ intestinal adenoma growth in mammals (e.g., activation of the oncogene *myc* in *APC*^−/−^ cells and dependence on Myc activity for adenoma growth \[[@bib24]\]), making our study potentially relevant to the onset of this pathology.

To generate *APC*^−/−^ intestinal adenomas, we introduced ISCs mutant for *APC1* and *APC2* (hereafter referred to as *APC*^*−/−*^) in the adult fly posterior midgut by flippase (FLP)-mediated mitotic recombination ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Clones derived from these cells were significantly bigger than control wild-type clones of similar age ([Figures 1](#fig1){ref-type="fig"}A--1C) and formed multi-layered structures bulging in the lumen of the gut ([Figures 1](#fig1){ref-type="fig"}D and 1E), as previously described \[[@bib19], [@bib20]\]. This distorted morphology is visible 10 days after clone induction (ACI; data not shown), but is more prominent at later stages. To address whether these adenomas induce cell competition, we then looked at the incidence of death in cells surrounding these clones. Using cleavage of PARP as a readout for caspase activation, we observed apoptotic cells in both control guts and guts containing *APC*^*−/−*^ cells ([Figures 1](#fig1){ref-type="fig"}F--1G′). However, although apoptotic cells were randomly distributed in control epithelia ([Figures 1](#fig1){ref-type="fig"}F, 1F′, and 1H, left graph), we found a 4-fold enrichment in apoptotic cells around *APC*^*−/−*^ adenomas ([Figures 1](#fig1){ref-type="fig"}G, 1G′, and 1H, right graph). Increased apoptosis was observed both among the differentiated cell types, i.e., enterocytes (recognized by their large polyploid nuclei; [Figure 1](#fig1){ref-type="fig"}I) and enteroendocrine cells (marked by expression of Prospero; [Figure 1](#fig1){ref-type="fig"}I′), and among ISCs (marked by expression on Delta; [Figure 1](#fig1){ref-type="fig"}I″). Overall, we conclude that growing *APC*^*−/−*^ adenomas induce elimination of nearby cells by apoptosis.

*APC*^*−/−*^-Induced Cell Competition Causes Attrition of Healthy Tissue {#sec2.2}
------------------------------------------------------------------------

The increased elimination of cells surrounding *APC*^*−/−*^ adenomas urged us to further examine the behavior of the host tissue in proximity of adenomas. By labeling the *APC* mutant and the wild-type chromosomes with different fluorescent markers, we could lineage trace simultaneously induced clones of cells originating either from *APC*^*−/−*^ (RFP-negative) or from wild-type (GFP-negative) stem cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Interestingly, we found that wild-type clones were dramatically smaller when grown in midguts containing *APC*^*−/−*^ adenomas ([Figures 2](#fig2){ref-type="fig"}B and 2C, right graph) than genetically identical control clones grown in wild-type epithelia ([Figures 2](#fig2){ref-type="fig"}A and 2C, left graph), with a median clone size of only ∼25% of their expected size. In addition, we found that the number of wild-type clones per gut drops drastically over time ([Figure S2](#mmc1){ref-type="supplementary-material"}A), with the majority of residual clones made by one cell only at 20 days ACI ([Figure 2](#fig2){ref-type="fig"}D), indicating accelerated clone extinction. Indeed, wild-type clones in control guts showed a much lower incidence of one-cell clones ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Altogether, these data indicate that *APC*^*−/−*^ adenomas engage in cell competition with surrounding wild-type cells and, by acting as supercompetitors, cause attrition of the host tissue.

Cell Competition Drives Tumor Growth {#sec2.3}
------------------------------------

Loss of healthy cells in a tumor-bearing environment is detrimental to organ function and compromises health \[[@bib25]\]. Therefore, we next asked whether we could protect wild-type tissue from elimination induced by *APC*^*−/−*^ adenomas by expressing inhibitors of apoptosis. Using the GeneSwitch system, which allows RU486 (mifepristone)-inducible Gal4-driven expression, we expressed the *Drosophila* Inhibitor of Apoptosis 1 (DIAP1) or baculovirus protein p35 directly after clone induction, across the posterior midgut in both progenitor cells and enterocytes \[[@bib22], [@bib26]\]. Remarkably, we found that inhibition of apoptosis by DIAP1 ([Figures 3](#fig3){ref-type="fig"}A--3C) or p35 ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C) expression was sufficient to fully restore growth of wild-type clones ([Figure 3](#fig3){ref-type="fig"}C; compare also to control clones in [Figure 1](#fig1){ref-type="fig"}C, left graph; p = 0.5694). This indicates that apoptotic induction alone can account entirely for host tissue attrition during cell competition.

Strikingly, the growth of *APC*^*−/−*^ adenomas was drastically reduced in guts in which the loss of neighboring tissue had been prevented ([Figures 3](#fig3){ref-type="fig"}A′, 3B′, 3D, [S3](#mmc1){ref-type="supplementary-material"}A′, [S3B](#mmc1){ref-type="supplementary-material"}′, [and S3D](#mmc1){ref-type="supplementary-material"}). In fact, the size of *APC*^*−/−*^ clones was statistically indistinguishable from that of wild-type clones within the same guts (compare the right graphs in [Figures 3](#fig3){ref-type="fig"}C and 3D; p = 0.4211). This was not an indirect effect of inhibition of turnover, since wild-type clone growth was instead rescued in these same guts ([Figures 3](#fig3){ref-type="fig"}A--3C and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). In addition, DIAP1 or p35 expression did not affect the behavior of control clones in control guts ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). Two complimentary experiments confirmed that this effect is due to inhibition of apoptosis specifically in the host tissue. First, expression of DIAP1 or p35 only in *APC*^*−/−*^ cells did not affect their clone size ([Figures 3](#fig3){ref-type="fig"}E--3G and [S3](#mmc1){ref-type="supplementary-material"}G--S3H), ruling out an autonomous effect. Second, conditional inhibition of apoptosis exclusively in the host tissue (see [Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D for genetic setup) reduced growth of *APC*^*−/−*^ adenomas to a similar extent as inhibition throughout the epithelium ([Figures 3](#fig3){ref-type="fig"}H--3J; compare the right graphs in [Figures 3](#fig3){ref-type="fig"}D and 3J; p = 0.7212). Collectively, these data demonstrate that tumor-host cell competition is essential to drive the growth of *APC*^*−/−*^ adenomas in the *Drosophila* adult midgut.

JNK Signaling Boosts *APC*^*−/−*^ Adenoma Growth Autonomously and via Cell Competition {#sec2.4}
--------------------------------------------------------------------------------------

We next wondered which pathways are involved in *APC*^*−/−*^ adenoma expansion. The Jun N-terminal kinase (JNK) pathway plays a fundamental role in modulating both cell proliferation and cell death in many tissues, including the fly intestine \[[@bib27], [@bib28], [@bib29]\], and has been shown to be required for loser cell elimination in several types of cell competition \[[@bib30], [@bib31]\]. Using a phospho-specific antibody that recognizes an activated form of JNK, we observed high JNK activation specifically in guts that contain *APC*^*−/−*^ adenomas ([Figures 4](#fig4){ref-type="fig"}B, 4B′, [S4](#mmc1){ref-type="supplementary-material"}A, and S4A′), but not in control wild-type ([Figures 4](#fig4){ref-type="fig"}A and 4A′) or heterozygous *APC*^*−/+*^ ([Figure S4](#mmc1){ref-type="supplementary-material"}B) guts. Hyper-activation of JNK was prominent both inside *APC*^*−/−*^ adenomas and in surrounding tissue ([Figure 4](#fig4){ref-type="fig"}B). This was not an effect of tissue aging \[[@bib28]\] because increased pJNK signal could be observed as early as 5 days ACI ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Importantly, pJNK staining was still present within *APC*^−/−^ clones in guts in which competition had been blocked by apoptosis inhibition ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F, arrowhead); however, its levels were reduced in small *APC*^*−/−*^ clones ([Figure S4](#mmc1){ref-type="supplementary-material"}F), indicating that clone size is important for JNK activation.

We next tested the relevance of JNK activation to *APC*^*−/−*^ adenoma growth and cell competition. Interestingly, inhibition of the pathway throughout the gut epithelium, by GeneSwitch-induced expression of the JNK inhibitor Puckered (Puc), rescued wild-type clone size ([Figures 4](#fig4){ref-type="fig"}C, 4D, and 4E). Notably, the growth of *APC*^*−/−*^ adenomas was severely reduced under these conditions ([Figures 4](#fig4){ref-type="fig"}C′, 4D′, and 4F). Since JNK can have a pro-proliferative effect, we then asked whether the reduction in *APC*^*−/−*^ clone growth was due to a cell-autonomous effect. Importantly, we found that JNK inhibition in *APC*^*−/−*^ cells, by expression of Puc or a dominant-negative version of JNK (JNK^DN^) caused a marked reduction in *APC*^*−/−*^ clone size ([Figures 4](#fig4){ref-type="fig"}G--4H and [S4](#mmc1){ref-type="supplementary-material"}G--S4I). This was accompanied by a reduction of the proliferation rate and of the proportion of ISCs in *APC*^*−/−*^ clones ([Figures 4](#fig4){ref-type="fig"}G--4J), both of which have been shown to be increased in *APC*^*−/−*^ tumors \[[@bib19], [@bib20], [@bib24]\]. This indicates that JNK signaling is required both for proliferation and for stem cell fate maintenance in *APC*^*−/−*^ cells. Note that dependence on JNK activity for clonal expansion is not a general feature of ISCs, as JNK signaling inhibition has no effect on the colonization of wild-type cells in control guts \[[@bib22]\]. Next, to dissect the role of JNK signaling in cell competition, we inhibited the pathway in non-tumor cells only. Importantly, inducible expression of either Puc or JNK^DN^ specifically in the host tissue severely reduced growth of *APC*^*−/−*^ adenomas ([Figures 4](#fig4){ref-type="fig"}K--4M and [S4](#mmc1){ref-type="supplementary-material"}J--S4L). Together, these data indicate that JNK signaling has a dual function: it is required in *APC*^*−/−*^ cells to promote their growth and in loser cells for their elimination by cell competition.

It has been shown that, in the fly intestine, expression of the secreted JAK/STAT cytokine Unpaired-3 (Upd-3) can be activated by JNK signaling upon stress or injury \[[@bib22], [@bib27], [@bib29]\]. Furthermore, the growth of *APC*^*−/−*^ clones has been reported to be JAK/STAT dependent \[[@bib24]\]. However, inhibition of JNK signaling in the host tissue by expression of JNK^DN^ did not abrogate elevation of JAK/STAT signaling in *APC*^*−/−*^ adenomas ([Figures S4](#mmc1){ref-type="supplementary-material"}M and S4N). Thus, inhibition of JNK signaling in neighboring cells blocks cell competition in a JAK/STAT-independent manner.

Tumor Growth Is Required for Cell Competition {#sec2.5}
---------------------------------------------

By monitoring competing clones at 10 and 20 days ACI, we observed that wild-type clones initially grew ([Figures 5](#fig5){ref-type="fig"}A and 5C, left graph) and subsequently shrunk ([Figures 5](#fig5){ref-type="fig"}B and 5C, right graph). This coincided with an increase in *APC*^*−/−*^ clone size ([Figures 5](#fig5){ref-type="fig"}A′, 5B′, and 5D), suggesting that *APC*^*−/−*^ clones need to attain a critical size to compete efficiently. Indeed, blocking *APC*^*−/−*^ clone growth by inhibiting JNK signaling or silencing of Myc \[[@bib24]\] was sufficient to rescue wild-type clone size ([Figures 5](#fig5){ref-type="fig"}E--5J). We found that guts containing *APC*^*−/−*^ clones with an average size of ∼30 cells were able to outcompete wild-type clones ([Figure S5](#mmc1){ref-type="supplementary-material"}A; compare to control size in [Figures 2](#fig2){ref-type="fig"}A and 2C, left graph), indicating that this is a sufficient size for *APC*^*−/−*^-induced competition. Notably, although *myc* is upregulated in *Drosophila APC*^*−/−*^ intestinal adenomas and required for their overgrowth \[[@bib24]\], we found that increasing Myc expression in host cells did not rescue their outcompetition ([Figure S5](#mmc1){ref-type="supplementary-material"}B) or inhibit *APC*^*−/−*^ adenoma growth ([Figures 5](#fig5){ref-type="fig"}K--5M). This indicates that, like in developing epithelia \[[@bib23]\], differences in Myc levels are not required for *APC*^*−/−*^-induced cell competition in the intestine.

Relative Differences in Hippo Activity Determine the Cell Competition Potential of *APC*^*−/−*^ Cells {#sec2.6}
-----------------------------------------------------------------------------------------------------

The Hippo pathway plays an important role in growth control and can inhibit proliferation and promote apoptosis via inhibitory phosphorylation of the downstream transcriptional co-activators YAP and TAZ (Yorkie \[Yki\] in *Drosophila*) \[[@bib32]\]. Given that Hippo signaling has been implicated in cell competition in developing tissues \[[@bib33], [@bib34], [@bib35]\] and that Wnt signaling induces YAP/TAZ activation in mammals \[[@bib36], [@bib37]\], we investigated whether Yki is active in *APC*^*−/−*^ adenomas and whether it plays a role in cell competition. First, we observed that activity of the microRNA and Yki target gene *bantam* was high (Bantam-GFP levels were low) in some *APC*^*−/−*^ clones ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Second, *diap1-*LacZ, another reporter of Yki activity, was consistently upregulated in *APC*^*−/−*^ adenomas ([Figures 6](#fig6){ref-type="fig"}A--6A″). Interestingly, *diap1*-LacZ upregulation was seen predominantly in small cells ([Figures 6](#fig6){ref-type="fig"}A--6A″, compare inset 1 to inset 2) and was observed throughout *APC*^*−/−*^ clones and not just at clone borders, where cell competition takes place, suggesting that upregulation of Yki activity is autonomous to *APC*^*−/−*^ cells and not a consequence of cell competition. Consistent with this, inhibiting cell competition by blocking apoptosis ([Figures 6](#fig6){ref-type="fig"}B--6B″) or JNK signaling ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D) in the host tissue did not affect the ectopic activation of *diap1-*LacZ, despite the severe reduction in clone size.

To test the involvement of Hippo signaling in cell competition, we aimed to level differences in Yki activity between *APC*^*−/−*^ clones and their surrounding host tissue. Thus, we removed one functional copy of the upstream inhibitory kinase Hippo (*hpo*^*42-47/+*^) or its upstream activator Expanded (*ex*^*ex1/+*^), with the aim of marginally decreasing pathway activity across the gut. Importantly, we found that halving the *hpo* or *ex* gene dosage fully rescued the growth ability of otherwise wild-type clones ([Figures 6](#fig6){ref-type="fig"}C--6F). This was not a consequence of a general hyper-proliferative response to *hpo* or *ex* heterozygosity, as it did not have any effect on clonal growth in otherwise wild-type guts ([Figures S6](#mmc1){ref-type="supplementary-material"}E--S6H). Thus, imperceptibly tweaking Hippo activity is sufficient to abrogate *APC*^*−/−*^-induced cell competition in this tissue. Strikingly, the growth of *APC*^*−/−*^ adenomas was severely reduced in *hpo*^*−/+*^ or *ex*^*−/+*^ heterozygous backgrounds ([Figures 6](#fig6){ref-type="fig"}C′--6E′ and 6G). This is extremely unexpected, because removing one copy of a tumor suppressor should instead promote the proliferative potential of tissues. In contrast, the median size of these *APC*^*−/−*^ clones reverted to that of wild-type clones in the same tissue (for *hpo*^*−/+*^, compare [Figures 6](#fig6){ref-type="fig"}D and 6D′ and the middle graphs in [Figures 6](#fig6){ref-type="fig"}F and 6G; p = 0.3744; for *ex*^*−/+*^, compare [Figures 6](#fig6){ref-type="fig"}E and 6E′ and the right graphs in [Figures 6](#fig6){ref-type="fig"}F and 6G; p = 0.7621). Importantly, this was not caused by a detrimental effect of Yki activity on *APC*^*−/−*^ adenomas, because autonomous overexpression of Yki in *APC*^*−/−*^ cells did not inhibit their growth ([Figures S6](#mmc1){ref-type="supplementary-material"}I--S6K). Notably, the suppression of *APC*^*−/−*^ adenoma growth by *hpo* heterozygosity was not due to a reduction in JNK (data not shown) or JAK-STAT ([Figures S6](#mmc1){ref-type="supplementary-material"}L and S6M) signaling. Altogether, these results show that Yki signaling is activated in *APC*^−/−^ adenomas and plays a role in *APC*^*−/−*^-induced cell competition in the intestine and that differences in Hippo signaling, rather than absolute Hippo activity, determine the cell competition potential of *APC*^*−/−*^ adenomas.

Discussion {#sec3}
==========

It has been well over a decade since the first reports of a connection between cancer-related genes and cell competition \[[@bib8], [@bib9]\]. These and a panoply of subsequent studies led to the long-standing hypothesis that cell competition contributes to cancer formation \[[@bib10], [@bib11]\]. Here we have investigated this directly, by exploiting the recent establishment of the adult *Drosophila* intestine as a model system to study adult tissue homeostasis and tumor formation \[[@bib15], [@bib18]\]. Our work shows that Wnt-induced intestinal adenomas directly compete with the host tissue. Importantly, we find that cell competition is an essential driver of tumor growth. Indeed, inhibiting cell competition suppresses over-proliferation in *APC*^*−/−*^ cells, effectively blocking tumor formation ([Figure 7](#fig7){ref-type="fig"}). Importantly, this finding demonstrates that the growth of cells with a mutation considered to be a major driver of colon cancer is not uncontrolled and that the cellular environment plays a deterministic role in the behavior of those cells. In this light, some previously reported observations might, at least in part, be explained by cell competition. For example, it has been reported that not all micro-metastases have the potential to immediately grow into secondary tumors \[[@bib38]\], a phenomenon called cancer dormancy \[[@bib38]\]. Based on our findings, we speculate that the interaction of such micro-metastasis with their environment, through cell competition, could play a deterministic role in their ability to grow or not. Consistent with this hypothesis, it has been shown that in developing *Drosophila* tissues cells with mutations in some tumor suppressor genes (e.g., *lgl* and *scribble*) can be eliminated by wild-type cells \[[@bib39]\]. It is only through acquisition of additional mutations (similarly to "second hit" mutations during tumorigenesis) that those cells overcome the tumor-suppressive environment of the host and overgrow \[[@bib31], [@bib40]\]. Furthermore, it has recently been found that naturally occurring cell competition in the thymus protects mice from developing leukemia \[[@bib41]\], lending further support to this notion.

Recently, it has been shown that some mutations involved in human colon cancer can give a competitive advantage to cells in the mouse gut. Specifically, oncogenic mutations in K-Ras \[[@bib42]\] or APC \[[@bib43]\] endow stem cells with a competitive advantage, which increases their chances of colonization. On the basis of clone population dynamics, those studies have proposed that cell-autonomous differences in cell proliferation or cell survival rates among wild-type and oncogenically mutated cells account for their colonization bias. Here we have taken a different approach, whereby at the same time as scoring adenoma growth we monitored and manipulated the cell survival probability of the host tissue. This has allowed us to uncover cell interactions among tumor and host cells that cause induction of cell death in surrounding normal tissue, a feature that we demonstrate to be essential to enable adenoma growth. In light of our findings, we suggest that a similar process may contribute to the colonization bias observed in the mouse intestine \[[@bib42], [@bib43]\].

We further show that growing *APC*^*−/−*^ adenomas cause accelerated extinction of wild-type competing clones, resulting in attrition of surrounding tissue. This is remarkable, considering that it has been shown that *APC* mutations induce a cytokine-rich pro-proliferative environment in and around adenomas, which should instead promote growth \[[@bib24]\]. This indicates that host tissues recede at sites of tumor growth, a process that is not only disadvantageous because it enhances tumorigenesis, but is also detrimental to organ performance. Since interfering with tumor growth inhibits competition and, vice versa, inhibiting cell competition blocks tumor growth, we propose that both events occur simultaneously and enhance one another in a feedforward loop. Our finding that apoptosis inhibition allows the host tissue to contain growing adenomas could have important implications for cancer therapy, as it could provide a strategy to prevent or delay a lethal aspect of cancer, namely organ failure \[[@bib25]\]. It further suggests that apoptosis inhibitors might constitute an unexplored arsenal in combination therapies against cancer. This is a radical suggestion, given that many anti-cancer chemo- and radiotherapies are, on the contrary, based on the use of wide-spectrum cell death inducers.

Our work identifies a new role for Yki activity in tumor growth. In particular, we show that *APC*^*−/−*^ tumors display increased Yki activity, consistent with previous findings \[[@bib36], [@bib37]\]. Since YAP/TAZ and Yki are oncogenes, it is paradoxical that halving the gene dosage of *hpo* or *ex*, both of which are Yki inhibitors and recognized/putative tumor suppressors, should inhibit adenoma growth. This points at a new unappreciated role of Hippo signaling, which provides *APC*^*−/−*^ adenomas with the ability to compete. Importantly, it further highlights that relative rather than absolute differences in Hippo activity are important for tumor growth. A *hpo* or *ex* heterozygous background (but, interestingly, not *yki* heterozygosity; [Figures S6](#mmc1){ref-type="supplementary-material"}O and S6P) most likely limits the ability of Hippo to inhibit Yki in the host tissue. We show that although that has no noticeable effect on the behavior of otherwise wild-type cells under normal conditions, it is sufficient to allow them to withstand the competition from *APC*^*−/−*^ adenomas. There are several possible mechanistic explanations for this observation. First, the Hippo pathway is an important sensor of cell density \[[@bib44]\]. This might be relevant because *APC*^*−/−*^ tumors disregard the normal morphology of the midgut epithelium and exhibit higher cell density \[[@bib20]\] ([Figure 1](#fig1){ref-type="fig"}). Therefore, one could speculate that leveling Yki activity could give surrounding cells a chance to be less sensitive to cell density and thereby prevent cell competition. Alternatively, *hpo* or *ex* heterozygosity may confer some resistance to cell death induction, as one of the targets of Yki is the inhibitor of apoptosis DIAP1 \[[@bib45]\]. Lastly, there is evidence that the crosstalk between Hippo and Wnt pathways is bidirectional and that, besides the previously discussed activation of YAP/TAZ by Wnt, the Hippo pathway can also restrict Wnt signaling \[[@bib46]\]. Reduced Hippo signaling in surrounding cells could therefore act as a positive feedback to facilitate Wnt activation in these cells.

Finally, our findings also reveal an important role of the JNK pathway in *APC*^*−/−*^-driven adenoma formation. As we show, JNK activation in *APC*^*−/−*^ cells and in patches of surrounding tissue is important to drive tumor growth. A similar activation of JNK has also recently been observed around, but not inside, intestinal *Notch*^*−/−*^ tumors \[[@bib21]\]. Interestingly, however, while *Notch*^−/−^ tumors rely on the niche microenvironment to supply proliferative JAK/STAT ligands, we find that *APC*^*−/−*^ tumors, which also require JAK/STAT activation \[[@bib24]\], do not depend on a supply from the niche. Both JNK and JAK/STAT pathways are involved in sensing stress, injury, and inflammation and enabling regeneration and repair in the *Drosophila* adult gut \[[@bib27], [@bib28], [@bib29]\]. This is particularly relevant because there are many reports that inflammation and stress influence tumorigenesis. For example, colitis, induced by dextran sodium sulfate feeding, can strongly promote carcinogenesis in APC^min^ mice \[[@bib47]\] and increase the colonization potential of p53 mutant cells \[[@bib43]\]. Furthermore, it has been shown that chronic inflammation causes a predisposition for colorectal cancer \[[@bib48]\], while treatment with anti-inflammatory drugs decreases this probability \[[@bib49]\]. In this regard, we speculate that targeting JNK signaling could provide a particularly effective therapeutic strategy, as it could simultaneously inhibit cancer cell growth and protect host tissue from competition-induced attrition.

Overall, our findings shed light on new potential strategies for cancer treatment. They suggest that the growth of early lesions or micro-metastases could be more effectively prevented by strengthening the surrounding healthy tissue, in addition to focusing on killing the cancer cells themselves, which is the main goal of current treatments.

Experimental Procedures {#sec4}
=======================

*Drosophila* Genetics and Stock Maintenance {#sec4.1}
-------------------------------------------

Detailed information about the *Drosophila* stocks is given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, along with a list of all the experimental genotypes.

Flies were grown at 25°C and fed on standard fly food containing yeast. For experiments using the GeneSwitch system \[[@bib50]\], food was supplemented with 40 or 200 μM RU486 (mifepristone; Sigma-Aldrich, M8046) in 80% EtOH or with an equal volume of 80% EtOH as control. Single-stem-cell-derived clones were generated by mitotic recombination using the FLP/FRT (flippase recognition target) system. 1 to 2 days after eclosion, fertilized female flies were heat shocked in a water bath at 37°C for 10 min. Adults were transferred to fresh vials every 2--3 days and were kept at 25°C until dissection at day 17 unless stated otherwise.

Immunostaining {#sec4.2}
--------------

Guts were dissected in PBS and fixed for 20 min at room temperature in PBS containing 3.7% formaldehyde and 0.025% Triton X-100. After several washes in 0.25% Triton X-100/PBS (washing buffer), guts were blocked for 30 min in a solution of 0.1% BSA/0.1% Triton X-100/PBS (blocking buffer). They were then incubated in the appropriate primary antibody diluted in blocking buffer overnight at 4°C. After several washes in washing buffer, guts were incubated for 2 hr at room temperature with the appropriate secondary antibody, followed by several washes in washing buffer. Samples were mounted in Vectashield (Vector Laboratories) on a borosilicate glass slide (no. 1.5, VWR International). A list of the antibodies used is given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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![*APC*^*−/−*^ Adenomas Eliminate Surrounding Cells\
(A--E) Posterior midguts harboring control (A and D) or *APC*^*−/−*^ (B and E) clones, marked by the absence of GFP (A and B) or by 2×GFP (D and E). (A) and (B) show a maximum intensity projection of multiple z sections in x/y. (D) and (E) show a reconstruction of all z sections in y/z. The graph in (C) displays the distribution of clone sizes (left, n = 176 clones; right, n = 164 clones).\
(F--I″) Analysis of cell death in posterior midguts harboring control (F and F′) or *APC*^*−/−*^ (G, G′, and I--I″) clones marked by the absence of hPARP-Venus. Immunostaining for cleaved hPARP (red) marks apoptotic cells. The graph in (H) displays the ratio of cleaved-hPARP-positive cells at clone borders (near) normalized to the rest of the tissue (far). Each dot represents one gut, and the black bar indicates the average ratio (±SD; n = 8 guts per condition). Apoptotic cells around *APC*^*−/−*^ adenomas are enterocytes (identified by a polyploid nucleus; I), anti-Prospero-positive enteroendocrine cells (I′) or anti-Delta-positive intestinal stem cells (I″); arrowheads point to apoptotic cells.\
Throughout the figures, colored lettering describes fluorescent-protein-positive and white lettering fluorescent-protein negative tissue, and dashed lines indicate clone borders. Unless stated otherwise, in the graphs each dot represents one clone, red bars indicate median clone sizes, and p values are displayed above graphs (Mann-Whitney test). Detailed genotypes are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Scale bars represent 50 μm.](gr1){#fig1}

![*APC*^*−/−*^ -Induced Cell Competition Causes Attrition of Healthy Tissue\
Posterior midguts harboring simultaneously induced GFP-negative WT (A, A″, B, and B″) and RFP-negative WT (A′ and A″) or *APC*^*−/−*^ (B′ and B″) clones. The graph in (C) displays the distribution of WT clone sizes (left, n = 106 clones; right, n = 227 clones). The graph in (D) shows the percentage of one-cell clones across a whole population of WT clones in guts containing *APC*^*−/*−^ clones dissected 10 or 20 days ACI (left, n = 179 clones; right, n = 74 clones; Fisher's exact test). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Cell Competition Fuels Tumor Growth\
(A--D) Posterior midguts harboring WT clones (A and B) and *APC*^*−/−*^ clones, (A′ and B′). Clones are marked by 2×GFP (WT) or by the absence of GFP (*APC*^*−/−*^). In (B) and (B′), cell death was blocked by inducible expression of DIAP1 (+DIAP1; 40 μM RU486). Control guts (A and A′) are of the same genotype as in (B) but were treated with carrier only (−RU486). The graphs in (C) and (D) display the distribution of WT (C; left, n = 59 clones; right, n = 63 clones) or *APC*^*−/−*^ (D; left, n = 87 clones; right, n = 161 clones) clone sizes.\
(E--G) Posterior midguts harboring *APC*^*−/−*^ clones marked by expression of GFP, with (F; +DIAP1) or without (E; control) additional expression of DIAP1. The graph in (G) displays the distribution of *APC*^*−/−*^ clone sizes with (right) or without (left) DIAP1 expression (left, n = 172 clones; right, n = 187 clones).\
(H--J) Posterior midguts harboring *APC*^*−/−*^ clones marked by the absence of RFP. In (I), cell death was blocked in host cells by expression of DIAP1 (+DIAP1; 40 μM RU486). Control guts (H) are of the same genotype as in (I) but were treated with carrier only (−RU486). The graph in (J) displays the distribution of *APC*^*−/−*^ clone sizes with (right) or without (left) DIAP1 expression in host cells (left, n = 160 clones; right, n = 218 clones).\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![JNK Signaling Boosts *APC*^*−/−*^ Adenoma Growth\
(A--B′) Posterior midguts stained with anti-phospho (active) JNK (pJNK, red) containing WT (A and A′) or *APC*^*−/−*^ clones (B and B′) marked by the absence of GFP.\
(C--F) Posterior midguts harboring WT clones, marked by 2×GFP (C′ and D′ and outlined in C and D), and *APC*^*−/−*^ clones, marked by the absence of GFP (C′ and D′). JNK signaling was blocked by inducible expression of Puckered (+Puc; 200 μM RU486; D and D′). Control guts (C and C′) are of the same genotype as in (D) but were treated with carrier only (−RU486). The graphs in (E) and (F) display the distribution of clone sizes for WT clones (E; left, n = 38 clones; right, n = 44 clones) and *APC*^*−/−*^ clones (F; left, n = 184 clones; right, n = 161 clones).\
(G--J) Posterior midguts harboring *APC*^*−/−*^ clones marked by expression of GFP with (H) or without (G) additional expression of Puckered within the clones and stained with anti-phospho H3 to mark mitotic cells (green) and anti-Delta to mark ISCs (white). The graphs in (I) and (J) display the percentage of *APC*^*−/−*^ Delta-positive stem cells (I) or the percentage of mitotic *APC*^*−/−*^ Delta-positive stem cells per gut (J). Each dot represents one gut, and the black bar indicates the average (±SEM; left, n = 14 guts; right, n = 23 guts; t test).\
(K--M) Posterior midguts harboring *APC*^*−/−*^ clones marked by the absence of RFP. In (L), JNK signaling was blocked in host cells by inducible expression of Puckered (+Puc; 40 μM RU486). Control guts (K) are of the same genotype as in (L) but were treated with carrier only (−RU486). The graph in (M) displays the distribution of *APC*^*−/−*^ clone sizes (left, n = 137 clones; right, n = 227 clones).\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Tumor Growth Is Required for Cell Competition\
(A--D) Posterior midguts harboring simultaneously induced GFP-negative WT (A and B) and RFP-negative *APC*^*−/−*^ (A′ and B′) clones, dissected 10 days (A) or 20 days (B) ACI. The graphs in (C) and (D) display the distribution of clone sizes for WT clones (C; left, n = 179 clones; right, n = 74 clones) or *APC*^*−/−*^ clones (D; left, n = 231 clones; right, n = 186 clones).\
(E--J) WT clones, marked by the absence of GFP, in posterior midguts harboring control *APC*^*−/−*^ clones (E and H) or *APC*^*−/−*^ clones expressing Puckered (F) or Myc^RNAi^ (I) specifically within the clone. The graphs in (G) and (J) display the distribution of WT clone sizes (G, left, n = 112 clones; G, right, n = 62 clones; J, left, n = 164 clones; J, right, n = 118 clones).\
(K--M) Posterior midguts harboring *APC*^*−/−*^ clones marked by the absence of RFP. Myc was inducibly expressed in host cells (L; +Myc; 40 μM RU486). Control guts (K) are of the same genotype as in (L) but were treated with carrier only. The graph in (M) displays the distribution of *APC*^*−/−*^ clone sizes (left, n = 119 clones; right, n = 114 clones).\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Differences in Hippo Activity Determine Cell Competition Potential of *APC*^*−/−*^ Cells\
(A--B″) Posterior midguts with *APC*^*−/−*^ clones, marked by the absence of RFP 17 days (B) or 20 days (A) ACI. Yki activity was detected by expression of *diap1*-LacZ (white, A′ and B′; green, A, A″, B, and B″). The magnifications in (A) display regions inside (region 1) and outside (region 2) *APC*^*−/−*^ clones, and arrowheads point at small *APC*^*−/−*^ mutant (white arrowheads) or small WT (red arrowheads) cells. Cell death was blocked in (B) by inducible expression of DIAP1 (40 μM RU486). The magnifications display regions containing *APC*^*−/−*^ clones, and arrowheads point at small *APC*^*−/−*^ mutant cells.\
(C--G) Guts containing simultaneously induced GFP-negative WT (C, D, and E) and RFP-negative *APC*^*−/−*^ (C′, D′, and E′) clones in control (C and C′), *hpo*^−*/+*^ (D and D′), or *ex*^−*/+*^ (E and E′) posterior midguts. The graphs in (F) and (G) display the distribution of *APC*^*+/+*^ (F; left, n = 304 clones; middle, n = 155 clones; right, n = 120 clones) or *APC*^*−/−*^ (G; left, n = 237 clones; middle, n = 183 clones; right, n = 158 clones) clone sizes from control (left), *hpo*^−*/+*^ (middle), or *ex*^−*/+*^ (right) guts.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Cell Competition Promotes Tumor Growth in *Drosophila*\
Schematic model depicting how cell competition affects *APC*^*−/−*^ adenoma growth. Growing *APC*^−/−^ adenomas in the adult *Drosophila* posterior midgut kill surrounding cells and cause host tissue attrition. JNK signaling activation in *APC*^−/−^ cells is required for their growth, whereas non-autonomous JNK activation in the host tissue is required for cell competition. *APC*^−/−^ cells also display higher Yki activity than host cells and this is required for cell competition. Inhibition of cell competition prevents adenoma growth, indicating that cell competition is an essential driver of tumor growth in this tissue.](gr7){#fig7}
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